CLINICAL PHARMACOKINETIC STUDY OF PROCETOFENE, A NEW HYPOLIPIDEMIC DRUG, IN VOLUNTEERS

  • 1 January 1978
    • journal article
    • research article
    • Vol. 16  (12) , 570-574
Abstract
The clinical pharmacokinetics of a new hypolipidemic drug, procetofene (Lipanthyl), were determined in 10 normolipemic volunteers after a single 300 mg dose and repeated 300 mg fractionated doses (b.i.d. [twice a day]) during 10 days, followed by an additional single dose (300 mg) on day 11. The peak plasma level of procetofenic acid, the circulating active metabolite, was observed after 4 or 6 h. A steady-state plasma level above 10 .mu.g/ml was reached on day 5 and maintained to day 10 on continued fractioned administration. This mean plasma level was not reached during the single-dose study. A double-exponential plasma decay curve was observed in volunteers after repeated doses; .alpha. phase, 5.27 .+-. 1.05 h; .beta. phase, 21.73 .+-. 1.07 h. As shown by the urinary excretion data, the drug is poorly absorbed by the digestive tract, i.e., only about 30% is absorbed.

This publication has 0 references indexed in Scilit: